Beneficial SGLT2 inhibitors (SGLT2In) effects in patients with left ventricular assist device (LVAD)

Key Points

• This research aims to assess the impact of SGLT2 inhibitors on patients with left ventricular assist devices (LVAD).
• Included patients with LVAD who started SGLT2 inhibitors three months post-implantation.
• Divided participants into SGLT2 inhibitor-treated and untreated subgroups.
• Conducted assessments including six-minute walk test, echocardiographic evaluations, and laboratory tests at baseline and follow-ups.
• SGLT2 inhibitor group showed significant increase in six-minute walk test distance (51.2 m and 78.7 m at follow-ups).
• No significant changes in left ventricular function and NT-proBNP levels were observed.
• Improved right ventricular function was indicated by reduced RVIT and increased TAPSE.
• Laboratory results indicated an increase in hemoglobin and a reduction in creatinine and glucose levels.

Structured PICO

Abstract